Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

The genetic basis of the joint hypermobility syndromes

Open access
Malfait, F., Hakim, A. J., De Paepe, A., Grahame, R.·2006·Rheumatology

Abstract

Rheumatologists have long considered that joint hypermobility is inherited. The familial aggregation is striking and the pattern of inheritance strongly points to an autosomal dominant mode. The first comprehensive description of symptomatic joint hypermobility in the rheumatological literature is attributed to Kirk, Ansell and Bywaters in 1967 [1]. They coined the term ‘hypermobility syndrome’ (HMS). Later, the recognition of the relatively benign prognosis of the HMS in terms of life-threatening complications led to the use of the term ‘benign joint hypermobility syndrome’ (BJHS) or latterly, the ‘joint hypermobility syndrome’ (JHS). Early workers believed that joint hypermobility merely represented the upper end of a Gaussian distribution of the range of normal physiological movement [2]. Later it became apparent that connective tissues other than joints, such as skin, bone and eye, participated in the connective tissue fragility seen in JHS. These clinical signs of connective tissue fragility are usually most prominent in the different forms of heritable disorders of connective tissue (HDCTs) such as Marfan syndrome (MFS), osteogenesis imperfecta (OI) and the Ehlers–Danlos syndromes (EDS). Marfan syndrome is an autosomal dominant disorder characterized by aortic dilatation, ectopia lentis, marfanoid habitus and mild to moderate joint hypermobility [3]. Osteogenesis imperfecta, another autosomal dominant HDCT, is mainly characterized by varying degrees of bone fragility, blue sclerae, short stature and mild joint hypermobility. The EDS comprise a clinically and genetically heterogeneous group of connective tissue diseases of which the principal clinical features are joint hypermobility, skin hyperextensibility, delayed wound healing with atrophic scarring and generalized connective tissue fragility [4]. There exists, however, a phenotypic overlap between these forms of HDCT. The marfanoid habitus (Table 1) for instance was once considered to be pathognomonic for MFS. This notion is no longer tenable. Marfanoid habitus can be seen in a host of HDCTs, as illustrated in Table 2. Similarly, the blue sclerae, once thought to occur only in OI are now considered to have a wider relevance as a non-specific pointer to collagen deficiency. Skin hyperextensibility (and associated bruising, delayed healing and atrophic scarring) originally identified exclusively with EDS, is also recognized in MFS [3]. Although brittle bones were initially considered to feature only in OI, a reduction in bone mineral density detected by Dual energy x-ray absorptiometry (DEXA) scanning has been demonstrated in both EDS [5] and MFS [6]. Features of the marfanoid habitus Features of the marfanoid habitus Marfan overlap is seen in the following Marfan overlap is seen in the following With recognition of the presence of mild fragility of connective tissues other than the joints in patients with JHS, it became evident that JHS is itself an under-recognized form of an HDCT. Patients with JHS can present mild expression of marfanoid habitus (Table 2), osteoporosis, blue sclerae, skin hyperextensibility, atrophic scarring or easy bruising [7, 8] (Table 3). Since these features can also be present in the most common form of EDS, the hypermobility type (or former type III), it seems increasingly likely that JHS is, if not identical, indistinguishable from the hypermobility type of EDS [9]. The patient presenting with joint hypermobility The patient presenting with joint hypermobility Clinical scientists, epidemiologists and geneticists have hitherto attempted to define clinical patterns of disease in their quest for reliable systems for classification and diagnosis. In the field of the HDCTs, the first attempt to produce sets of consensus-derived criteria was the Berlin nosology of 1986 [10], which aimed at covering the whole range of HDCTs. With the advent of molecular genetics, the Berlin nosology fell rapidly out of date and revised criteria for MFS (the Ghent criteria) [11] and EDS (the Villefranche criteria) [12] emerged in 1996 and 1998, respectively, to be followed by the validated 1998 Brighton criteria for JHS in 2000 [13]. Such sets of criteria are useful in defining cohorts of patients for research studies, but represent poor substitutes for precise laboratory tools capable of identifying specific genetic causes of disease. To date, the genetic basis of joint hypermobility remains largely unknown. Study of the HDCTs, such as EDS, MFS and OI, can give important insights into the mechanisms underlying joint hypermobility, since joint hypermobility is a prominent feature in all of these syndromes, albeit to a variable degree. The connective tissue matrix consists of fibrillary collagens, fibrillins, elastins and proteoglycans, and together these structural components provide the unique mechanical properties of the joint capsule and the surrounding ligaments and tendons. Joint hypermobility can be present in a mild form in MFS, caused b

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kei268

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 171

Metadata

Authors
Malfait, F., Hakim, A. J., De Paepe, A., & Grahame, R.
Venue
Rheumatology
Published
2006-01-17
Volume
45
Issue
5
Pages
502-507
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2130705772
Cited by
171
References
8
FWCI
3.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The genetic basis of the joint hypermobility syndromes. https://app.cochat.ai/papers/10.1093/rheumatology/kei268
The paper
Malfait, F., Hakim, A. J., De Paepe, A., & Grahame, R. (2006). The genetic basis of the joint hypermobility syndromes. Rheumatology. https://doi.org/10.1093/rheumatology/kei268

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.